EP Patent

EP3042901A1 — Hepatitis c virus inhibitors

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2016-07-13 · 10y expired

What this patent protects

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

USPTO Abstract

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Drugs covered by this patent

Patent Metadata

Patent number
EP3042901A1
Jurisdiction
EP
Classification
—
Expires
2016-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.